Search

Your search keyword '"Pulmonary fibrosis -- Care and treatment -- Development and progression"' showing total 18 results
Start Over Descriptor "Pulmonary fibrosis -- Care and treatment -- Development and progression" Publication Year Range Last 50 years
18 results on '"Pulmonary fibrosis -- Care and treatment -- Development and progression"'

1. Idiopathic Pulmonary Fibrosis: A Clinical Overview

Author

Henderson, Pa-C Miranda and Dexter, Mls Kathy Holmes

Subjects
Blood -- Medical examination, Bacterial pneumonia -- Care and treatment -- Development and progression, Pulmonary fibrosis -- Care and treatment -- Development and progression, Pneumonia -- Care and treatment -- Development and progression, Health
Abstract

Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease and the most common type of idiopathic https://www.clinicaladvisor.com/home/topics/pulmonology-information-center/covid-19-vs-ild-complex-pulmonary-differential-diagnosis/, is characterized by chronic fibrosis and progressive scarring of the lung tissues.[sup.1] [...]

Published
2024

2. United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis

Subjects
United Therapeutics Corp., Medical research, Medicine, Experimental, Pulmonary fibrosis -- Care and treatment -- Development and progression, Biotechnology industry, Treprostinil, Business, Business, international, Tyvaso (Medication)
Abstract

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half [...]

Published
2024

3. Findings in Pulmonary Fibrosis Reported from Yale University (Microrna-33 Deficiency In Macrophages Enhances Autophagy, Improves Mitochondrial Homeostasis, and Protects Against Lung Fibrosis)

Subjects
Pulmonary fibrosis -- Care and treatment -- Development and progression, Homeostasis -- Research, Autophagy (Cytology) -- Research, MicroRNA -- Health aspects, Macrophages -- Health aspects, Cellular control mechanisms -- Research, Health
Abstract

2023 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Lung Diseases and Conditions - Pulmonary Fibrosis are discussed [...]

Published
2023

4. Recent Findings in Acute Respiratory Distress Syndrome Described by Researchers from Guangzhou Medical University (Inositol Alleviates Pulmonary Fibrosis By Promoting Autophagy Via Inhibiting the Hif-1 Alpha-slug Axis In Acute Respiratory ...)

Subjects
Inositol -- Usage -- Physiological aspects, Pulmonary fibrosis -- Care and treatment -- Development and progression, Health
Abstract

2023 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Lung Diseases and Conditions - Acute Respiratory [...]

Published
2023

5. Investigators from Heilongjiang University of Chinese Medicine Target Pulmonary Fibrosis (Protective Effect of Combined Moxibustion and Decoction Therapy On Bleomycin-induced Pulmonary Fibrosis In Rats Under Nuclear Factor-kappa B/transforming ...)

Subjects
Pulmonary fibrosis -- Care and treatment -- Development and progression, Moxibustion -- Usage -- Physiological aspects, Health
Abstract

2023 FEB 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Lung Diseases and Conditions - Pulmonary Fibrosis have [...]

Published
2023

6. Research from Kangwon National University Has Provided New Study Findings on Idiopathic Pulmonary Fibrosis (L-carnosine Attenuates Bleomycin-Induced Oxidative Stress via NFkB Pathway in the Pathogenesis of Pulmonary Fibrosis)

Subjects
Pulmonary fibrosis -- Care and treatment -- Development and progression, Carnosine -- Usage -- Physiological aspects -- Health aspects, Oxidative stress -- Health aspects, Transcription factors -- Physiological aspects -- Health aspects, Health
Abstract

2023 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on idiopathic pulmonary fibrosis have been published. According to [...]

Published
2023

7. School of Basic Medical Sciences Reports Findings in Transforming Growth Factors (Epoxyeicosatrienoic Acids Inhibit the Activation of Murine Fibroblasts By Blocking the Tgf-beta 1-smad2/3 Signaling In a Ppar Gamma-dependent Manner)

Subjects
Arachidonic acid -- Physiological aspects, Pulmonary fibrosis -- Care and treatment -- Development and progression, Metabolites -- Physiological aspects -- Health aspects, Transforming growth factors -- Physiological aspects -- Health aspects, Cytochrome P-450 -- Physiological aspects -- Health aspects, Health
Abstract

2022 DEC 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Intercellular Signaling Peptides and Proteins - Transforming Growth Factors [...]

Published
2022

8. Studies from Chang Gung University Have Provided New Data on Pulmonary Fibrosis (2,3,5,4 '-tetrahydroxystilbene-2-o-beta-d-glucoside Ameliorates Bleomycin-induced Pulmonary Fibrosis Via Regulating Pro-fibrotic Signaling Pathways)

Subjects
Pulmonary fibrosis -- Care and treatment -- Development and progression, Respiratory agents -- Research, Pharmacology, Experimental, Bleomycin -- Complications and side effects, Cellular signal transduction -- Research, Phytochemicals -- Testing -- Health aspects, Health
Abstract

2022 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Lung Diseases and Conditions - Pulmonary Fibrosis have been [...]

Published
2022

10. New Idiopathic Pulmonary Fibrosis Study Findings Reported from Universidad Autonoma de Madrid (Epidemiology and real-life experience in progressive pulmonary fibrosis)

Subjects
Pulmonary fibrosis -- Care and treatment -- Development and progression, Epidemiology -- Reports, Health
Abstract

2023 NOV 27 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Fresh data on idiopathic pulmonary fibrosis are presented in a new report. According to [...]

Published
2023

11. Reports from University of Helsinki and Helsinki University Hospital Advance Knowledge in Idiopathic Pulmonary Fibrosis (KIF15 missense variant is associated with the early onset of idiopathic pulmonary fibrosis)

Subjects
Boehringer Ingelheim GmbH, Pulmonary fibrosis -- Care and treatment -- Development and progression, Pharmaceutical industry -- Analysis, Health, University of Helsinki
Abstract

2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators publish new report on idiopathic pulmonary fibrosis. According to news reporting out of [...]

Published
2023

13. Boehringer Ingelheim's latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Subjects
Boehringer Ingelheim Pharmaceuticals Inc., Medical research, Medicine, Experimental, Respiratory agents, Pulmonary fibrosis -- Care and treatment -- Development and progression, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

- Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine - Potential new treatment for [...]

Published
2022

14. New Findings from Institute for Pulmonary Diseases of Vojvodina Describe Advances in Idiopathic Pulmonary Fibrosis (Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review)

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Pulmonary fibrosis -- Care and treatment -- Development and progression, Pain -- Care and treatment, Health
Abstract

2022 AUG 5 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on idiopathic pulmonary fibrosis is the subject of a new report. [...]

Published
2022

15. FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2

Subjects
FibroGen Inc., Medical research, Medicine, Experimental, Pulmonary fibrosis -- Care and treatment -- Development and progression, Biotechnology industry, Clinical trials, Business, international, Law
Abstract

(GlobeNewswire) - FibroGen, Inc.(NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, [...]

Published
2020

16. FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2

Subjects
FibroGen Inc., Medical research, Medicine, Experimental, Pulmonary fibrosis -- Care and treatment -- Development and progression, Biotechnology industry, Clinical trials, Banking, finance and accounting industries, Business
Abstract

SAN FRANCISCO, Dec 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- FibroGen, Inc. (NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab [...]

Published
2020

17. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration *: role in preventing lung injury and fibrosis in bleomycin-challenged mice *. (laboratory and animal investigations)

Author

Li, YingJi, Azuma, Arata, Takahashi, Satoru, Usuki, Jiro, Matsuda, Kuniko, Aoyama, Akinori, and Kudoh, Shoji

Subjects
Macrolide antibiotics -- Evaluation, Pulmonary fibrosis -- Care and treatment -- Development and progression, Health, Evaluation, Care and treatment, Development and progression
Abstract

Background and objective: Although the pathogenesis of interstitial pneumonia and pulmonary fibrosis are not well understood, it has been reported that inflammatory cells, especially neutrophils, and the injurious substances produced [...]

Published
2002

18. InterMune Canada Inc release: game changing therapy for idiopathic pulmonary fibrosis now available in Canada

Subjects
Respiratory tract diseases -- Care and treatment -- Development and progression, Pulmonary fibrosis -- Care and treatment -- Development and progression, Business, Chemicals, plastics and rubber industries
Abstract

Following Health Canada's market approval of Esbriet (pirfenidone) on 1 Oct 2012, InterMune Canada Inc has announced that the only treatment indicated for mild to moderate idiopathic pulmonary fibrosis (IPF) [...]

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results